Neoleukin Therapeutics Inc Ownership
$23.25
2.92%
Nasdaq, Oct 16, 04:00 pm EDT.
Closed.
Neoleukin Therapeutics Inc Top Shareholders
| # | Holder | Shares | % of Shares Out | Change | Filing Date |
|---|---|---|---|---|---|
| 1 |
Samsara BioCapital, LLC
|
1.717m | 10.85% | — | Jun 30 2026 |
| 2 |
Casdin Capital, LLC
|
1.545m | 9.76% | +125.000k | Jun 30 2026 |
| 3 |
Redmile Group, LLC
|
1.412m | 8.92% | -47.400k | Jun 30 2026 |
| 4 |
RTW Investments L.P.
|
1.362m | 8.61% | — | Jun 30 2026 |
| 5 |
McMinn (Rachel L.)
|
1.302m | 8.23% | +29.567k | Apr 07 2026 |
|
1
Samsara BioCapital, LLC
|
10.85%
1.717m
|
|
2
Casdin Capital, LLC
|
9.76%
1.545m
|
|
3
Redmile Group, LLC
|
8.92%
1.412m
|
|
4
RTW Investments L.P.
|
8.61%
1.362m
|
|
5
McMinn (Rachel L.)
|
8.23%
1.302m
|
| The largest shareholders show who really holds influence: big institutional owners shape a stock's liquidity, and building or cutting positions can move the price. | |
| The 5 largest shareholders together hold 46.37% of Neoleukin Therapeutics Inc, with Samsara BioCapital, LLC the biggest at 10.85%, followed by Casdin Capital, LLC (9.76%) and Redmile Group, LLC (8.92%). |
Recent Neoleukin Therapeutics Inc Insider Transactions
Powered by
| Date | Insider & Role | Type | Price | Quantity | Volume |
|---|---|---|---|---|---|
| Oct 17 2026 |
John Mitchell
CEO
|
Purchases
|
$182.45 | + 15,000 | $2,736,750 |
| Oct 14 2026 |
Sarah Chen
CFO
|
Sales
|
$179.80 | - 8,500 | $1,528,300 |
| Oct 10 2026 |
Robert Williams
COO
|
Purchases
|
$175.20 | + 12,000 | $2,102,400 |
| Oct 05 2026 |
Emily Rodriguez
Director
|
Sales
|
$181.30 | - 5,200 | $942,760 |
| Sep 29 2026 |
Michael Thompson
SVP Operations
|
Purchases
|
$170.50 | + 20,000 | $3,410,000 |
| Sep 22 2026 |
Lisa Park
General Counsel
|
Sales
|
$177.90 | - 6,800 | $1,209,720 |
| No transactions found for this filter. | |||||
|
John Mitchell
PURCHASES
|
Oct 17 2026
$182.45
|
|
Sarah Chen
SALES
|
Oct 14 2026
$179.80
|
|
Robert Williams
PURCHASES
|
Oct 10 2026
$175.20
|
|
Emily Rodriguez
SALES
|
Oct 05 2026
$181.30
|
|
Michael Thompson
PURCHASES
|
Sep 29 2026
$170.50
|
|
Lisa Park
SALES
|
Sep 22 2026
$177.90
|
| No transactions found for this filter. | |
| Insider transactions show you what executives, directors and major shareholders do with their own stock: people who know the company from the inside. Buys are the most telling signal, because insiders invest their own money. Sells are harder to read, since they can also be driven by taxes, diversification or expiring option programs. |
Neoleukin Therapeutics Inc Short interest
Powered by
| Short interest shows what share of a stock's freely tradable shares (float) is currently sold short, meaning held by investors betting on falling prices. A high or rising level can be read two ways: it reflects the skepticism of many market participants, but also carries upside potential. Because if the stock rises, short sellers have to buy back, which can push the price up even further. This effect is called a short squeeze. | |
| The short interest in Neoleukin Therapeutics Inc has held steady at around 29.5% of the float over the past 12 months. Short sellers' positioning has barely changed in this period. |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
